Ask AI
ProCE Banner Series

Targeting Rare Genomic Alterations in Advanced Thyroid Cancer: What Endocrinologists Need to Know

Join us for a live CME/ABIM MOC–certified workshop series tailored to endocrinologists on managing advanced thyroid cancer with genomic alterations in NTRKRET, and BRAF, including expert guidance on biomarker testing, review of the latest clinical data on targeted therapies, and discussion of patient cases. Register now!

  ACPE
  | AMA
  | ANCC
  | AMA
Credits Available


Who Should Attend

This program is intended for endocrinologists and other healthcare professionals who care for patients with thyroid cancer.

All Events

Targeting Rare Genomic Alterations in Advanced Thyroid Cancer: What Endocrinologists Need to Know

Past Events

January

31

2023

10:00 AM - 11:00 AM Pacific Time (PT)

In-person

Private Event -- San Francisco VA Medical Center

February

02

2023

10:30 AM - 12:00 PM Mountain Time (MT)

In-person

Private Event -- Arizona Endocrinology Center

February

13

2023

11:30 AM - 12:30 PM Central Time (CT)

Virtual

March

01

2023

4:00 PM - 5:00 PM Mountain Time (MT)

Virtual

CCO Simulcast | Host Group CO, Pueblo, Colorado

Topics

  • Introduction
  • Overview of Thyroid Cancer: Most Common Genetic Drivers
  • Biomarker Testing in Thyroid Cancer
  • Clinical Data and Current Indications of Therapies Targeting Common Genetic Drivers in Advanced Thyroid Cancer
  • Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with thyroid cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with thyroid cancer
  • Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive thyroid cancer and RET inhibition in RET-altered thyroid cancer
  • Manage treatment-related symptoms associated with the treatment of RET-altered or NTRK fusion–positive cancer
  • Refer eligible patients with NTRK fusion–positive and RET-altered thyroid cancer for ongoing clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

In partnership with American Society for Clinical Pathology

Supported by educational grants from:

Bayer HealthCare Pharmaceuticals Inc.
Blueprint Medicines
Genentech, a member of the Roche Group
Lilly

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191